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ABSTRACT
Background: Spinal cord injury (SCI) carries debilitating lifelong consequences and, therefore, requires careful
review of different treatment strategies.
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Methods: An extensive review of the English literature (PubMed 1990 and 2019) was performed regarding recent
advances in the treatment of SCI; this included 46 articles written over 28 years.
Results: Results of this search were divided into five major modalities; neuroprotective and neuroregenerative
pharmaceuticals, neuromodulation, stem cell-based therapies, and various external prosthetic devices. Lately,
therapeutic strategies were mainly focused on two major areas: neuroregeneration and neuroprotection.
Conclusion: Despite recent advancements, more clinical trials on a larger scale and further research are needed to
provide better treatment modalities of this devastating neurological disease.
Keywords: Exoskeleton, Neuromodulation, Spinal cord injury, Spine, Stem cells, Trauma

INTRODUCTION
Spinal cord injury (SCI) is a devastating illness resulting in neurological deficits and poor quality
of life. It has an annual incidence of 15–40 cases per million and a prevalence of more than
1 million cases in North America.[12] The incidence and prevalence of traumatic SCI is expected
to increase as the population ages, particularly secondary to traumatic falls in the elderly.[45] The
annual cost of SCI exceeds 7 billion dollars.[12]
This literature review focuses on the advances in pharmacology, stem cell technologies,
neuromodulation, and external prosthetics. Several pharmacological therapies have already
been tested in the past and are currently being investigated. Further, both neuroprotective and
neuroregenerative drugs are being implemented in clinical trials.[45] Stem cell therapy trials are
also ongoing, but more data are needed from Phase II clinical trials to document efficacy.

MATERIALS AND METHODS
Peer-reviewed articles were searched through PubMed using search terms “acute SCI,” “SCI
treatment,” “neuromodulation,” “stem cell therapy for SCI,” “SCI pharmaceuticals,” and “SCI
is is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-Share Alike 4.0 License, which allows others
to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.
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exoskeleton from 1990 to 2019 (English journals). Using
appropriate inclusion and exclusion criteria, 46 peer-reviewed
articles were used. All studies focused on current
advancements in the management of SCI, including stem cell
therapies, neuromodulation, and external prosthetics.

methylprednisolone infusion within 8 h of injury should be
performed only in certain situations, taking into consideration
the associated complications.[27,45]

RESULTS AND DISCUSSION

Three drugs, naloxone, tirilazad, and nimodipine, were
studied for their neuroprotective abilities. They all have
Phase III randomized controlled trials which have not
shown any difference in NASCIS motor score recovery
or the American Spinal Injury Association (ASIA) motor
score between treatment and placebo groups.[5,6,27,37,45]
Tirilazad is a nonglucocorticoid 21-aminosteroid that
attenuates peroxidation of neuronal lipid membranes.
Tirilazad had no difference in NASCIS motor score between
tirilazad and 24 h infusion of methylprednisolone.[6,45] The
neuroprotective value of naloxone is believed to be due to
blockage of the neurotoxic effects of the endogenous opioid
dynorphin A. Nimodipine is a calcium channel blocker
that inhibits calcium-dependent activation of lytic cellular
enzymes as well as presynaptic glutamate release.[5,37,45]

Neuroprotective and neuroregenerative pharmaceuticals
[Tables 1and 2]
Methylprednisolone
Several neuroprotective and neuroregenerative pharmaceutical
drugs have been investigated for SCI management.
A well-known neuroprotective agent, methylprednisolone,
has been associated with improved neurological outcomes.
It decreases the peroxidation of membrane lipids and
posttraumatic inflammation.[45] Despite its effects in preclinical
settings, it does still remain controversial in the clinical setting.
A Cochrane review found no significant effect for a high-dose
24 h infusion of methylprednisolone in terms of motor
recovery at 6 months.[7,45] However, when started within 8 h
after injury, an additional 4-point improvement in National
Acute SCI Study (NASCIS) motor score was seen.[7,45] Its
association with increased rates of gastrointestinal hemorrhage
and wound infections also adds to its controversy.[7,45] A
randomized controlled trial evaluating high-dose 48 h infusion
showed no difference in NASCIS motor score recovery
versus 24 h infusion.[6,45] The guidelines now suggest that

Naloxone, tirilazad, and nimodipine

Riluzole
Riluzole, a sodium channel blocker approved for the
treatment of amyotrophic lateral sclerosis, has been studied in
preclinical models of SCI. It diminishes secondary injury by
blocking activation of sodium channels and reducing release
of neuronal glutamate.[41,45] Phase I/II trials evaluating the

Table 1: Neuroprotective pharmaceuticals.
Drug
IV Methylprednisolone

[6,7,45]

Naloxone[5,37,45]
Tirilazad[5,37,45]

Nimodipine[5,37,45]

Riluzole[14,22,45]
Minocycline[8,15,28,45]
Basic fibroblast growth factors[45,44]

Mechanism

Evidence on efficacy

Neuroprotection through reduction
of membrane lipids peroxidation and
posttraumatic inflammation
Inhibition of neurotoxic effect of endogenous
opioid dynorphin A
Decreases peroxidation of lipid neuronal
membranes

Limited evidence on neuroprotective properties,
most recent studies failed to prove real benefit as
treatment in acute SCI
No evidence of improvement in NASCIS or ASIA
motor scores
No evidence of improvement in NASCIS or ASIA
motor scores
No difference in NASCIS motor score when
compared to 24 h infusion of methylprednisolone
No evidence of improvement in NASCIS or ASIA
motor scores

Calcium channel blocker that prevents
calcium-dependent activation of apoptotic
enzymes and blocks release of presynaptic
glutamate
Sodium channel blocker, reduces sodiumdependent glutamate release diminishing
neuronal injury
Modified form of tetracycline (antibiotic),
reduces inflammation, neuronal apoptosis, and
microglial activation
Neuroprotection by reducing glutamatemediated excitotoxicity

ASIA: American Spinal Injury Association, NASCIS: National Acute Spinal Cord Injury Study
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Phase I trials have shown a gain of 15.5 in motor
score. Phase IIB and III trials are ongoing
Phase II trials have shown improvement in motor
score (14 points). Phase III trials are ongoing
Pending results from Phase I/II clinical trials
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Table 2: Neuroregenerative pharmaceuticals.
Drug
G-CSF

[31,43]

GM-1 ganglioside (Sygen)[16]
Cethrin[13,45]
Anti-Nogo[45]

Mechanism

Evidence on efficacy

Inhibition of TNF-alpha and IL-1 beta, promoting cell
survival
Component of neuronal membranes enhances axonal
regeneration in laboratory studies
Bacterial-derived toxin, BA-210, and a biohemostatic
adhesive inhibit the Rho pathway of inhibitory proteins
and promotes axonal growth
Monoclonal antibody binds and inhibits Nogo (protein
that blocks axonal growth in the CNS through activation
of Rho pathway), promoting neuronal regeneration

Phase I/IIa clinical trials have shown
improvement in ASIA motor score (P<0.01)
Randomized placebo-controlled trial did
not show benefits
Benefits shown in Phase I/IIa trials.
Improvement in AISA motor score
Currently in early phase clinical trials

CNS: Central nervous system, G-CSF: Granulocyte colony-stimulating factor, ASIA: American Spinal Injury Association, TNF: Tumor necrosis factor,
IL: Interleukin

safety and pharmacokinetics of riluzole began in humans in
2010 and were completed in 2012.[14,22,45] In the Phase I trial,
a gain of 15.5 points in motor score for patients with cervical
injuries was found for the riluzole group of 24 patients over
the comparison registry group of 26 patients.[22] At 180 days,
there was a gain of 31.2 points for patients with cervical
injuries for 24 riluzole patients and of 15.7 points for 26
registry patients.[22] There was a gain of 9 points in pinprick
scores in riluzole patients with complete or incomplete
cervical injuries versus registry patients.[22] A Phase IIB/III
double-blinded randomized controlled trial was started in
2014 looking at the safety and neuroprotective efficacy of
riluzole in patients with acute cervical SCI. These results will
provide Class I evidence regarding the use of riluzole.
Minocycline
Minocycline, a modified form of tetracycline, is another
neuroprotective agent that has shown some promise
in animal models.[15,45] In animal models of SCI, it has
been shown that minocycline decreases neuronal and
oligodendrocytes apoptosis, microglial activation in addition
to anti-inflammatory effects.[15] In randomized controlled
Phase II clinical trials, minocycline was associated with
14-point gain in motor score over placebo in patients with
cervical SCI.[8,22,45] Pinprick scores in these motor-incomplete
patients were 14 points higher than placebo.[22,28,45]
Phase III clinical trials will be able to provide further
evidence regarding its use.
Fibroblast growth factor
Basic fibroblast growth factor has shown to provide
neuroprotection by improving functional and respiratory
parameters in animal models by reducing glutamate-mediated
excitotoxicity.[44,45] There are current Phase I/II trials that are
further investigating this therapy. Furthermore, cytokine
granulocyte colony-stimulating factor which inhibits tumor

necrosis factor-alpha and interleukin-1 beta, promoting cell
survival has shown benefits in two nonrandomized studies.[31,43]
GM-1 ganglioside (Sygen)
A neuroregenerative agent, GM-1 ganglioside (Sygen) has
been shown to enhance axonal regeneration in laboratory
studies.[45] Gangliosides are important glycolipid molecules
that are components of neuronal membranes. Randomized
placebo-controlled trial using this agent did not show any
difference in neurological recovery in patients at 6 months.[16,45]
Cethrin
Cethrin is a permeable paste that can be applied to spinal cord
dura postinjury that is a combination of a bacterial-derived
toxin, BA-210, and a biohemostatic adhesive. It inhibits the
Rho pathway of inhibitory proteins and promotes axonal
growth in vitro.[45] Phase I/IIa trials were done where it was
applied to dura in patients with complete injuries, and no
complications were seen at 1-year follow-up.[13,45] In fact, in
patients with cervical injuries receiving cethrin, there was an
improvement in ASIA motor score.[45]
Anti-Nogo
Another neuroregenerative drug, anti-Nogo, is a monoclonal
antibody made to bind to Nogo-A, and has been shown to
promote neural regeneration.[45] Nogo-A is a protein that
blocks axonal growth in the central nervous system.[45] This
anti-Nogo agent is still under investigation. Many of these
neuroprotective and neuroregenerative agents have shown
promising results and future studies will be helpful in
establishing their efficacy.
Neuromodulation [Table 3]
It is well known that neuromodulation, the use of
electrical stimulation to alter neuronal circuitry, has
Surgical Neurology International • 2020 • 11(2)
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Table 3: Other modalities; neuromodulation, stem-cell transplant, and prosthetic devices.
Modality

Mechanism

Evidence on efficacy

Neuromodulation
Spinal cord stimulation (epidural and
transcutaneous)[3,20,23,29]
Brain stimulation (transcranial direct current
stimulation and transcranial magnetic
stimulation)[1,4,11,17,25,36,38]
Stem cell-based therapies[10,30,33,39,40,42,46]

Improves neuronal connections
and circuits within the spinal cord
in the remaining intact tracts

Some benefits and improved functional
outcomes shown in several studies

Precursors for neuronal
regeneration. Oligodendrocyteinduced remyelination, axonal
elongation, and tract regeneration

Phase I clinical trials showed promising
results, however, phase II/III trials, and
ethical and legal concerns are still need
to be addressed

Prosthetic devices[9,19,21,35]

Providing physical assistance,
restoration of a certain level of
physical activity, and improvement
in cardiovascular health and gait
parameters

Several studies showed improvement in
functional outcomes and restoration of
certain level of physical activity

been tried in various neurological disorders including
SCI. Neuroplasticity-mediated functional recruitment of
axons (particularly spared axons) to potentiate sprouting,
regeneration, and formation of new interconnections
between neurons forms the basis of modern
neuromodulation techniques. This is complemented with the
presence of some intact ascending and descending circuits
in patients with SCI, making neuromodulation a feasible
option.[29] Spinal cord stimulation, one of the forms of
neuromodulation, is a rapidly growing method for SCI. For
spinal cord stimulation, epidural or transcutaneous method
may be used, and clinical studies have already demonstrated
some improvement in motor function with these methods.
[3,20,23]
Besides, spinal cord stimulation techniques, brain
stimulation, and peripheral nerve stimulation are other
approaches to neuromodulation in SCI.[29] Several studies
have demonstrated functional improvement in volitional
movements of lower limbs and hand dexterity in patients
with SCI.[3,17] However, whether neuromodulation is
affordable and accessible to all patients remains a major
challenge.[29]

Spinal cord stimulation

Activity-dependent plasticity

Brain stimulation for SCI

Moreover, the concept of activity-dependent plasticity has
been recently employed to achieve substantial improvements
in motor function, based on the recent finding that
neurorehabilitation is the only treatment option which can
be offered to SCI patients for long-term improvement in
motor function.[26] In this model, high-intensity training
combined with electrical neuromodulation has shown to
improve neuronal connections and circuits within the spinal
cord by working synergistically at least in a subpopulation of
patients.[26] This holds great promise for recovery of motor
function after SCI.

Brain stimulation for SCI is also currently being employed.
Transcranial direct current stimulation and transcranial
magnetic stimulation are two main approaches that are being
used to augment the neuronal plasticity between the spinal
cord and the brain in individuals with SCI.[29] Several studies
have already demonstrated to improve functional outcomes
from using transcranial direct current stimulation in patients
with motor complete SCI.[17,36,38] Transcranial direct current
stimulation is a noninvasive method to deliver direct current
with the use of scalp electrodes.[17] Transcranial magnetic
stimulation is another noninvasive approach that delivers
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With respect to spinal cord stimulation, epidural spinal
stimulation has well been tested in patients with chronic pain
and most recently in patients with SCI. This method involves
surgical placement of electrodes onto the dorsal surface of the
spinal cord.[29] Several studies utilizing neuromodulation in
patients with SCI ASIA A and B demonstrated an improved
ability to make lower extremity voluntary movements
following epidural stimulation of their spinal cord.[3,20,23]
Moreover, with respect to the effects on upper body, one case
study demonstrated improvements in handgrip strength and
motor strength of the upper extremities in patients following
epidural spinal stimulation once a day.[34] Unlike the epidural
method, transcutaneous stimulation is another method
and is a noninvasive approach to spinal cord stimulation. It
involves placement of electrodes onto the skin surface of a
patient. Aside from experimental studies on animals, more
clinical trials and studies are needed to fully ascertain the
advantages as well as long-term side effects of spinal cord
stimulation for SCI.[29]

Shah, et al.: Spinal cord injury management

magnetic waves to the brain and has shown improvements
in hand function in studies on patients with tetraplegia. Fine
motor tasks and handgrip strength improved with the use of
transcranial magnetic stimulation.[2,18] Transcranial magnetic
stimulation can also have a positive impact on patient’s
walking speed as evidenced by one of the trials.[32] Larger
scale trials are needed to assess these promising results. In
addition, although deep brain stimulation has already been
tested in experimental studies on animals, its potential in
treating patients with SCI still needs to be elucidated with
clinical trials and further research.[24]
Brain–machine interfaces
Brain–machine interfaces are another modern tool for
patients with SCI. These devices, which can be used to
control various prosthetic devices such as the exoskeleton
as well as directly stimulate paralyzed muscles, have already
demonstrated improved outcomes in patients with SCI
through several recent studies.[1,4,11,25] Clinical trials for
the use of brain–machine interfaces and their computer
algorithms are ever increasing as further research into
advances in technology, feasibility and accessibility of these
devices are still needed. In conclusion, due to increasing
promising results, neuromodulation for SCI will remain a
rapidly growing field in the upcoming years.
Stem cell-based therapies [Table 3]
Stem cell-based therapies and cellular scaffolds have yielded
promising progress with respect to neuronal repair.[10]
Phase I clinical trials have demonstrated that transplantation
of olfactory ensheathing cells can be a safe, promising
option to aid in neuronal repair in patients with SCI, but
more Phase II clinical trials are still needed.[33,42] Several
trials have also demonstrated the safe use of transplanted
neuroprotective Schwann cells for nerve repair in patients
with SCI, but clinical trials assessing the actual efficacy of this
method are still ongoing.[39,40,46] In addition, several clinical
trials have also demonstrated safety in using stem cells
from various sources for SCI, but there are many more that
are in the process of recruiting patients for transplantation
of various stem cells.[10] Ethical and tumorigenesis concerns
with stem cell-based therapies, however, will certainly need
to be addressed as their research evolves.[10]
In vitro manipulation of the embryonic stem cells (ESCs)
Recently, in vitro manipulation of the ESCs differentiation
to neuronal and glial lineages under controlled conditions
has shown promising results after transplantation in animal
models of acute SCI.[30] These included oligodendrocyteinduced remyelination, axonal elongation, and tract
regeneration. However, legal and ethical drawbacks have

limited the employment of ESC in the treatment of SCI
patients. This might be largely attributed to the destruction
of the blastocyst on isolation of the cells.[30] Moreover,
development of teratomas after ESCs transplantation in
numerous animal models has raised significant concerns
about the functionality of these cells as a potential therapeutic
avenue in SCI management.[30]
Various cell-based therapies
Despite extensive research exploring various cell-based
therapies such as transplantation of oligodendrocyte precursors,
induced pluripotent stem cells, bone marrow-derived
(BM-MSCs), adipose-derived (AD-MSCs), and umbilical cord
(U-MSCs),[30] there have been a lack of large Phase III clinical
trials investigating the therapeutic efficacy of stem cell therapy.
Prosthetic devices [Table 3]
Robotic exoskeletons or powered exoskeletons have emerged
as an advantageous rehabilitation tool for certain disabled
individuals with SCI. The studies provided preliminary
evidence on efficacy of exoskeletons on cardiovascular health,
energy expenditure, body composition, gait parameters, level
of physical activity, neuropathic pain level, and quality of life.
They can be used to restore a certain level of physical activity
years after injury.[9,19,35] Body weight supported treadmill
training and locomotion training with driven gait orthosis
are now considered essential component in the rehabilitation
of SCI patients. According to the meta-analysis of powered
exoskeletons, <5% of SCI patients have the ability to ambulate
without any physical assistance.[35] However, following an
exoskeleton training program, 67% of patients were able to
walk with exoskeleton-assisted ambulation without physical
assistance.[35] This meta-analysis included exoskeletons such
as ReWalkTM, EksoTM, and IndegoTM. In addition, even in
complex training situations, there were no adverse events, falls,
or fractures.[35] Furthermore, the neurologically controlled
exoskeleton HALTM has recently been Food and Drug
Administration approved for use in the United States. This
system has been proven to be beneficial in the rehabilitation of
patients with chronic spinal cord injuries.[21] This technology
is constantly being evolved, and it is important to strive
for an interdisciplinary team approach to provide greater
accessibility to this technology. This might help patients to
preserve the physical capacity before restoration becomes
necessary. The future of prosthetic devices is bright for SCI
patients and will continue to be investigated.

CONCLUSION
We investigated the advancements in neuroprotective
pharmacology, stem cell technologies, neuromodulation,
and various external prosthetics for the treatment of SCI.
Surgical Neurology International • 2020 • 11(2)
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However, more clinical trials and research will continue to
establish their efficacy.
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